share_log

康寧傑瑞製藥-B:自願公告 - JSKN033用於治療HER2表達的晚期或轉移性實體瘤的I/II期臨床試驗在澳大利亞獲批

ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - A PHASE I/II CLINICAL TRIAL OF JSKN033 FOR THE TREATMENT OF HER2-EXPRESSING ADVANCED OR METASTATIC SOLID TUMORS WAS APPROVED IN AUSTRALIA

香港交易所 ·  Dec 7, 2023 23:05
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more